June 2022

Dear WIPO Re:Search Members and Friends,

As many of you have heard by now, after 10 successful years of implementation, WIPO Re:Search will cease its activities on December 31, 2022. We are proud of all that the Consortium has achieved with your support and engagement, including facilitation of over 180 early-stage R&D collaborations to catalyze innovation for diseases that disproportionately affect the world’s poorest communities, and expansion of R&D capacity in low- and middle-income countries.

As we celebrate the Consortium’s decade of successes, I am excited to share that BVGH will be continuing its global infectious disease R&D partnering, alliance management, and capacity building initiatives through a new program to launch in early 2023. Stay tuned for further details.

WIPO Re:Search will remain active throughout 2022. Ongoing collaborations will continue until the end of this year. I invite you to read about new collaborations involving Pfizer Inc., Universidad de la República (Uruguay), Merck KGaA, Darmstadt, Germany*, University of Zambia, Swiss Tropical and Public Health Institute, and University of Cape Coast (Ghana) in this issue.

COVID-19 continues to pose a significant threat to the health and well-being of our global community. Demonstrating its continued contributions to pandemic preparedness and R&D, Takeda recently announced that it has received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare for Nuvaxovid®, a novel recombinant protein-based COVID-19 vaccine, for primary and booster immunization in individuals aged 18 and older.

As always, please share this Snapshot with your colleagues.

Sincerely,

Jennifer Dent, President & CEO
BIO Ventures for Global Health

*The business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics in the US and Canada.
Cornerstones of Collaboration

Sharing Expertise to Advance Antimalarial Drug Discovery

Knowledge exchange, and the sharing of expertise between the public and private sectors, not only leverages different R&D perspectives, but can be a key component in overcoming obstacles for neglected disease drug development. With an estimated 241 million malaria cases and over 625,000 malaria deaths worldwide in 2020, new therapeutics are urgently needed. Dr. Gloria Serra at Universidad de la República (Uruguay) has developed novel cyclopeptide compounds with promising antimalarial activity. BVGH coordinated a call between Dr. Serra and experts from Pfizer Inc., who shared non-confidential information on strategies for improving the compounds’ solubility and bioavailability.

Identifying Novel Drugs for Schistosomiasis from Zambian Natural Products

Up to 700 million people around the world are at risk of schistosomiasis infection. Praziquantel is the only approved treatment for schistosomiasis. Reliance on a single agent for treatment and control increases the risk that resistance will develop. Additional antischistosomal drugs with novel mechanisms of action are needed. Dr. Peter Cheuka, Lecturer and Researcher of Medicinal Chemistry and Drug Discovery at University of Zambia, is working toward the discovery and development of novel antischistosomal drugs derived from Zambian natural products. With support from Merck KGaA, Darmstadt, Germany*, Prof. Jennifer Keiser, Professor of Neglected Tropical Diseases at Swiss Tropical and Public Health Institute, will screen selected natural product extracts collected by Dr. Cheuka for antischistosomal activity.
Catalyzing Leishmaniasis and Malaria Drug Discovery through Compound Sharing

Annually, leishmaniasis affects up to one million people, and malaria affects an estimated 241 million people. Due to high burdens of these diseases in low-resource communities, toxicity of some current therapeutics, and increasing drug resistance, it is necessary to develop new treatments that are both effective and broadly accessible. As part of its commitment to Open Innovation, Merck KGaA, Darmstadt, Germany will share the Open Global Health Library with Dr. Isaac Attah at the University of Cape Coast (Ghana). Dr. Attah will screen the library to identify novel compounds with anti-promastigote and antiplasmodial activity.

*The business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics in the US and Canada.

BVGH FundFinder Featured Awards

**RSTMH 2022 Annual Meeting Travel Scholarships**

RSTMH members are invited to apply to receive a travel scholarship to attend the RSTMH Annual Meeting 2022, held October 11-12, 2022, in Liverpool, UK. Any RSTMH member who has not received a scholarship or a grant in the previous four years can apply (unless selected to present an abstract at the RSTMH Annual Meeting 2022). Priority will be given to early career professionals and students, residents of low- or middle-income countries (LMICs), and individuals who have not attended an international conference before. A travel scholarship is an award of a maximum of £2,000 and is expected to cover round-trip economy airfare, visa costs, hotel, meal expenses, and travel expenses. Applications are due June 24, 2022. Learn more and apply [here](#).

**Additional Funding Opportunities**

- [NIH Lasker Clinical Research Scholars Program](#) – Application Deadline: June 24, 2022.
- [Mastercard Foundation Scholars Program at KNUST](#) – Application Deadline: July 29, 2022.
- [NIAID Contract Opportunity to Develop a Novel Vaccine Adjuvant](#) – Application Deadline: October 14, 2022.
- [Boehringer Ingelheim Fonds (BIF) Travel Grants](#) – Applications must be submitted at least six weeks, but not more than six months, before anticipated travel.
- [Boehringer Ingelheim Fonds (BIF) Travel Grants](#) – Applications are accepted on a rolling basis; fellowships are awarded quarterly.

For more information about BVGH FundFinder, please email Cathy Manner.
## Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 15-17, 2022</td>
<td>World Health Summit Regional Meeting</td>
<td>Rome, Italy and Virtual</td>
</tr>
<tr>
<td>June 20-25, 2022</td>
<td>Commonwealth Heads of Government Meeting</td>
<td>Kigali, Rwanda</td>
</tr>
<tr>
<td>June 23, 2022</td>
<td>Kigali Summit on Malaria and NTDs</td>
<td>Kigali, Rwanda and Virtual</td>
</tr>
<tr>
<td>August 1-6, 2022</td>
<td>WorldLeish 7</td>
<td>Cartagena, Colombia</td>
</tr>
<tr>
<td>August 7-10, 2022</td>
<td>11th International Conference on Emerging Infectious Diseases 2022</td>
<td>Atlanta, Georgia, USA</td>
</tr>
<tr>
<td>August 23-25, 2022</td>
<td>9th International Toxinology Meeting</td>
<td>Oxford, UK and Virtual</td>
</tr>
<tr>
<td>September 13-15, 2022</td>
<td>Neglected Tropical Disease NGO Network Conference 2022</td>
<td>Kathmandu, Nepal and Virtual</td>
</tr>
<tr>
<td>October 4-5, 2022</td>
<td>COR-NTD Annual Meeting 2022</td>
<td>Virtual</td>
</tr>
<tr>
<td>October 11-12, 2022</td>
<td>RSTMH Annual Meeting 2022</td>
<td>Liverpool, UK</td>
</tr>
</tbody>
</table>

*The business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics in the US and Canada. **MSD is a trademark of Merck & Co., Inc., Kenilworth, NJ, USA.